Apotex a ‘standout’ stock since IPO despite Trump tariff threat, analysts say
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Apotex traded around $37 a share last Friday — more than 30% above its $28 IPO debut — after rebounding from an 8% drop that followed the U.S. tariff announcement on July 21.
- Apotex's June 10 listing raised $1.3-billion, making it the largest life-sciences and pharma IPO in Canadian history and the TSX's biggest listing in five years.
- National Bank analyst Nathan Po called the stock a "standout" versus earlier Canadian healthcare IPOs (Jamieson Wellness, DRI Healthcare, DentalCorp, Bausch + Lomb), maintaining an "outperform" rating and a $43 price target.
- U.S. tariffs of 100% on generic pharmaceuticals take effect August 1, 2028, rising to 200% in 2029; with two years to run, Po expects the rate to be walked back or carved out, and TD Cowen's Michael Nedelcovych said the news doesn't yet "create cause for serious concern."
- Apotex is currently the only supplier of generic Ozempic in Canada after production problems at Dr. Reddy and Aspen Pharmacare sidelined those competitors until at least late October.
- Scotiabank analysts estimate Apotex could be added to the Solactive Canada Broad Market Cap index as early as August 5, with potential inclusion in the MSCI Canada Small Caps and FTSE Canada Small Caps later this year.
Why it matters: Apotex pulled 46% of its $374-million FY2026 revenue from the U.S., so even a distant 2028 tariff deadline is enough to spook investors — the 8% selloff proves it. With the August 12 earnings call and possible August 5 index inclusion both landing before fall, analysts are betting the two-year runway gives Canadian and industry negotiators time to extract a generic-drug carve-out.
